Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

GP38 identified as key viral toxin and vaccine target in Crimean-Congo hemorrhagic fever virus research

A recent study published in Science Translational Medicine involving scientists from the U.S. Army Medical Research Institute of Infectious Diseases in collaboration with scientists from the Albert Einstein College of Medicine and the University of California-Berkeley have advanced discoveries surrounding the viral glycoprotein GP38 expressed by the Crimean-Congo hemorrhagic fever virus (CCHFV).

8 Apr 2025

Clinical trial demonstrates safety of targeted treatment approach for deadly brain tumor in children

A Phase I clinical trial demonstrated that a targeted approach to treating a deadly brain tumor in children called diffuse intrinsic pontine glioma (DIPG) is safe, reported Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center investigators.

3 Apr 2025

Fusion proteins enable the creation of monoclonal antibodies

The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to advance research projects.

26 Mar 2025

New monoclonal antibody shows promise in treating mucormycosis

Mucormycosis, a fungal infection caused by Mucorales, has high mortality rates in people with weakened immune systems and those suffering from severe trauma like burns, blast injuries or victims of natural disasters.

22 Mar 2025

Clinical trial investigates osteoporosis medication for type 1 diabetes

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States and a top research center for diabetes and other life-threatening illnesses, is leading a phase 1/2 clinical trial investigating an osteoporosis medication as a way to improve beta cell health in people with early type 1 diabetes.

19 Mar 2025

Targeting MARCO enhances cancer immunotherapy effectiveness

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO.

13 Mar 2025

Vanderbilt researchers aim to use AI to develop antibody therapies for any target

An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.

8 Mar 2025

Nasal spray may offer new hope for traumatic brain injury patients

A new study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one day be an effective treatment for traumatic brain injury (TBI).

27 Feb 2025

Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for adults with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy, irrespective of PD-L1 expression level or tumor histology.

14 Feb 2025

Inhaled antibody therapy shows promise for COVID-19 treatment

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

12 Feb 2025

NIH clinical trial examines investigational therapy for dengue

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease.

11 Feb 2025

AI predicts effective treatment for rare disease using existing medications

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD).

5 Feb 2025

NIH-supported clinical trial to test experimental treatment for dengue

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease.

31 Jan 2025

Study reveals abelacimab’s potential to improve anticoagulation safety for AFib patients

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and efficacy. While ischemic stroke rates were slightly higher, they were not statistically significant, warranting further phase 3 trials for confirmation.

23 Jan 2025

New imaging protocol enhances visualization of rare bone marrow cells

Bone marrow plays a crucial role in maintaining hematopoietic stem cells and bone homeostasis. However, research has been hindered by a lack of effective markers and monoclonal antibodies to accurately identify rare LepR+ stromal cells.

21 Jan 2025

Tofacitinib reduces SARS-CoV-2 infection risk in patients with PTPN2 deficiency

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in PTPN2.

17 Jan 2025

CAR-NK cells offer safer, more accessible treatment for lymphoma

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to patients.

15 Jan 2025

A new era of targeted therapy with antibody–drug conjugates

TBC

From Sino Biological Inc. 16 Dec 2024

Targeted gene therapy shuts down cancer cells' energy centers

Researchers are shining a light on cancer cells' energy centers – literally – to damage these power sources and trigger widespread cancer cell death.

14 Dec 2024

Next-generation cell-penetrating antibodies could transform cancer treatment

A news feature on the research paper "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition" by Rackear et al. was published in Oncotarget's Volume 15 on November 22, 2024, titled "Advancements in cell-penetrating monoclonal antibody treatment."

11 Dec 2024